eurasian
swine
influenza
viru
siv
first
report
pig
circul
european
pig
popul
eurasian
siv
first
report
china
occur
frequent
pig
sinc
pandem
siv
detect
mexico
spread
rapidli
countri
china
itali
unit
state
canada
three
subtyp
report
pig
global
pig
serv
mix
vessel
suscept
infect
human
avian
influenza
virus
may
pandem
threat
public
health
sporad
human
infect
eurasian
siv
emerg
europ
china
vaccin
primari
effect
measur
control
siv
infect
might
restrict
exampl
vaccin
may
effect
prevent
divers
viral
strain
manifest
less
immunogen
act
inadequ
speed
combat
newlyemerg
season
potenti
pandem
strain
approach
includ
viral
cultur
mammalian
insect
cell
suggest
produc
pandem
season
influenza
vaccin
low
level
express
protein
unknown
risk
antigen
cell
obstacl
combat
pandem
therefor
urgent
need
develop
altern
rapid
measur
cope
request
pandem
exampl
passiv
immun
deliv
specif
antibodi
recipi
could
protect
anim
infect
neutral
monoclon
antibodi
mab
viru
function
either
inhibit
viru
attach
membran
fusion
suscept
cell
studi
prove
mab
could
use
effect
prevent
treatment
influenza
viru
infect
howev
effect
neutral
mab
avail
prevent
control
siv
infect
product
function
antibodi
highli
depend
structur
integr
protein
tradit
proteinbas
immun
difficulti
gener
mab
conformationsensit
target
dnabas
immun
solv
problem
nativ
protein
express
vivo
deliv
form
dna
immunogen
requir
process
protein
product
purif
furthermor
correct
conform
protein
critic
induct
function
activ
antibodi
yet
sensit
structur
tend
damag
vitro
protein
product
process
express
intact
immunogen
vivo
dnabas
immun
appear
best
approach
induc
mab
desir
biolog
activ
herein
eukaryot
express
plasmid
pcineoha
construct
use
immunogen
prepar
mab
hemagglutin
ha
protein
subtyp
swine
viru
prepar
character
five
mab
evalu
protect
efficaci
mice
infect
homolog
heterolog
subtyp
virus
experi
procedur
involv
anim
approv
anim
welfar
ethic
censor
committe
harbin
veterinari
research
institut
hvri
anim
experi
studi
approv
anim
ethic
committe
hvri
chines
academi
agricultur
scienc
licens
syxk
heilongjiang
two
viral
strain
use
virus
propag
specificpathogen
free
spf
embryon
chicken
egg
canin
kidney
mdck
cell
store
use
mdck
cell
cultur
dulbecco
modifi
essenti
medium
dmem
contain
vv
fetal
bovin
serum
hyclon
ut
usa
incub
vv
atmospher
monolay
mdck
cell
plate
inocul
serial
dilut
viru
strain
dilut
five
replic
cytopath
effect
cpe
observ
daili
number
well
show
patholog
chang
record
titer
calcul
describ
previous
dilut
done
five
repetit
viral
rna
extract
allanto
fluid
use
viral
rna
extract
kit
qiagen
shanghai
china
virusspecif
cdna
obtain
use
influenza
univers
revers
transcript
primer
amv
revers
transcriptas
takara
dalian
china
ha
gene
amplifi
use
ha
genespecif
primer
clone
vector
takara
dalian
china
sequenc
use
abi
prism
dna
analyz
appli
biosystem
shanghai
invitrogen
china
fulllength
ha
clone
pcineo
use
specif
primer
introduc
nhe
ixho
restrict
site
result
plasmid
pcineoha
purifi
use
qiaminiprep
kit
qiagen
per
manufactur
protocol
extract
plasmid
identifi
use
doubl
digest
nhe
xho
new
england
biolab
whitbi
canada
recombin
plasmid
transform
compet
cell
coloni
screen
via
pcr
confirm
insert
gene
segment
plasmid
sequenc
conduct
use
abi
dna
automat
sequenc
plasmid
dna
pcineoha
use
immunogen
develop
mab
studi
briefli
fiveweekold
femal
balbc
mice
inject
intramuscularli
im
plasmid
dna
steril
phosphat
buffer
salin
pb
ph
mice
receiv
two
boost
plasmid
dna
threeweek
interv
mice
spleen
collect
asept
use
euthan
anesthesia
techniqu
mab
produc
use
techniqu
similar
describ
previous
splenocyt
fuse
myeloma
cell
hybridoma
cell
line
secret
antibodi
ha
screen
ha
antibodi
indirect
elisa
subclon
least
three
time
limit
dilut
method
ascit
fluid
prepar
clone
hybridoma
balbc
mice
isotyp
obtain
mab
determin
use
mous
immunoglobulin
isotyp
kit
zyme
laboratori
inc
usa
accord
manufactur
instruct
hemagglutin
inhibit
hi
test
perform
evalu
mab
reactiv
describ
previous
briefli
serial
twofold
dilut
purifi
ascet
fluid
mix
four
ha
unit
viru
hemagglutin
plate
incub
min
chicken
red
blood
cell
ad
well
incub
anoth
min
rule
nonspecif
inhibit
ascet
fluid
produc
inject
myeloma
cell
use
neg
control
hi
titer
express
reciproc
highest
ascet
dilut
complet
inhibit
hemagglutin
four
ha
unit
viru
mab
repeat
three
time
neutral
test
nt
perform
use
plate
mixtur
twofold
serial
dilut
mab
viru
suspens
contain
incub
h
use
inocul
mdck
cell
one
hundr
microlit
dmem
ad
well
incub
three
day
cpe
observ
everi
h
neutral
titer
present
reciproc
highest
antibodi
dilut
caus
reduct
viru
dilut
repeat
five
time
examin
whether
antiha
mab
recogn
ha
protein
western
blot
use
examin
bind
abil
mab
ha
protein
approxim
purifi
viru
subject
sdspage
nativ
page
transfer
nitrocellulos
membran
membran
probe
differ
mab
follow
secondari
hrpconjug
goat
antimous
antibodi
kpl
gaithersburg
md
usa
ascet
fluid
produc
inject
myeloma
cell
use
neg
control
mdck
cell
infect
strain
multipl
infect
moi
incub
h
incub
monolay
wash
twice
pb
fix
methanol
min
cell
incub
separ
differ
mab
h
neg
ascet
fluid
bound
antibodi
process
immunoperoxidas
stain
use
alkalin
phosphataselabel
mous
igg
dilut
extens
wash
pb
peroxidas
activ
reveal
incub
nitro
blue
tetrazolium
chlorid
nbt
phosphat
bcip
pb
min
mab
select
evalu
protect
efficaci
siv
high
hi
nt
titer
total
sixweekold
spf
balbc
mice
use
evalu
protect
efficaci
mab
mice
n
pretreat
intramuscularli
mab
two
group
neg
ascet
fluid
two
group
dose
per
mg
mous
bodi
weight
viral
challeng
remain
group
mice
n
pretreat
intramuscularli
neg
ascet
fluid
use
normal
control
h
mice
intranas
challeng
homolog
viru
heterolog
viru
respect
mice
monitor
weight
chang
clinic
symptom
two
week
twoday
interv
three
mice
per
subgroup
euthan
day
postchalleng
pc
sampl
includ
nasal
turbin
lung
spleen
kidney
collect
viru
titrat
egg
remain
five
mice
per
group
observ
daili
weight
chang
clinic
sign
infect
haencod
gene
amplifi
clone
pcineo
vector
confirm
recombin
plasmid
correct
pcineoha
digest
nhe
ixho
restrict
analysi
nucleotid
sequenc
electrophoresi
result
reveal
pcineoha
plasmid
digest
two
fragment
consist
size
haencod
gene
pcineo
vector
respect
figur
sequenc
result
confirm
haencod
gene
success
clone
pcineo
vector
hybridoma
cell
line
secret
antiha
antibodi
screen
elisa
five
mab
ha
select
subclon
least
three
time
posit
hybridoma
use
produc
mab
mice
obtain
ascit
fluid
collect
character
isotyp
mab
igm
respect
figur
concentr
immunoglobulin
rang
elisa
hi
nt
titer
five
mab
determin
hi
nt
indic
mab
hi
neutral
activ
highest
hi
nt
titer
mab
show
hi
neutral
activ
show
highest
elisa
activ
tabl
mdck
cell
use
assess
whether
obtain
mab
recogn
nativeform
ha
protein
immunohistochemistri
ih
assay
five
mab
show
strong
specif
reaction
mdck
cell
wherea
immunoreact
observ
normal
mdck
cell
neg
control
figur
black
color
signal
visual
cell
indic
mab
abl
detect
nativeform
ha
protein
cell
mdck
cell
use
assess
whether
obtain
mab
recogn
nativeform
denaturedform
ha
protein
western
blot
mab
react
strongli
kda
ha
protein
mdck
cell
denatur
figur
nativ
form
figur
suggest
mab
might
recogn
linear
epitop
noninfect
mdck
cell
show
reaction
protect
efficaci
mab
evalu
mice
two
differ
strain
ha
gene
show
ident
bodi
weight
chang
monitor
twoday
interv
mous
viru
titer
titer
calcul
five
repetit
lung
nasal
turbin
spleen
kidney
detect
day
challeng
compar
normal
control
mice
mab
pretreat
mice
show
obviou
clinic
symptom
challeng
challeng
homolog
viru
weight
chang
observ
mab
mice
wherea
weight
loss
nonmabtr
mice
moreov
compar
mice
normal
control
group
weight
loss
mice
challeng
heterolog
viru
tabl
figur
moreov
less
weight
loss
mice
follow
challeng
heterolog
viru
replic
mice
detect
day
challeng
mab
pretreat
group
detect
viru
lungnasalspleenkidney
mice
follow
challeng
nonmabtr
group
challeng
viru
replic
mean
titer
nasal
turbin
lung
tabl
contrast
mab
pretreat
group
challeng
two
three
mice
reveal
detect
viru
replic
lung
one
mous
display
detect
viru
replic
nasal
turbin
mean
titer
respect
wherea
viru
detect
nonmabtr
mice
titer
lung
nasal
turbin
respect
viru
detect
spleenkidney
mab
pretreat
nonmabtr
mice
challeng
antibodymedi
passiv
immun
provid
protect
invad
pathogen
sinc
commerci
vaccin
avail
swine
influenza
viru
china
import
develop
passiv
immunotherapeut
prevent
control
subtyp
siv
infect
pig
ha
glycoprotein
induc
neutral
antibodi
provid
immedi
acquir
immun
influenza
virus
therefor
gener
neutral
mab
antigen
site
ha
glycoprotein
regard
criterion
evalu
immun
influenza
virus
believ
constitut
main
correl
protect
studi
develop
five
mab
ha
protein
eukaryot
recombin
plasmid
pcineoha
immunogen
mice
sinc
hi
neutral
test
demonstr
mab
hi
neutral
activ
may
specul
neutral
activ
result
correct
fold
ha
protein
ih
assay
show
mab
react
ha
protein
infect
mdck
cell
indic
mab
western
blot
show
mab
recogn
kda
ha
protein
kda
larger
expect
kda
ha
protein
indic
ha
might
glycosyl
immun
antiha
antibodi
capabl
confer
protect
influenza
viru
infect
anim
human
sinc
mab
highest
hi
nt
titer
examin
protect
efficaci
mice
challeng
homolog
heterolog
strain
siv
consid
siv
isol
lethal
mice
investig
mab
protect
efficaci
bodi
weight
detect
viru
titer
lung
spleen
kidney
nasal
turbin
three
day
challeng
data
confirm
onedos
pretreat
mice
mab
suffici
provid
complet
protect
homolog
siv
infect
studi
also
evalu
abil
mab
protect
mice
challeng
pandem
viru
heterolog
strain
compar
normal
control
mice
replic
challeng
viru
mabtreat
mice
also
inhibit
lung
nasal
turbin
result
demonstr
treatment
mice
mab
also
limit
suscept
mice
infect
siv
includ
ha
gene
recent
ealineag
viru
suggest
broad
crossprotect
might
confer
pandem
viru
result
suggest
mab
could
provid
complet
protect
homolog
inhibit
diseas
develop
caus
heterolog
mab
therefor
promis
treatment
swine
influenza
viru
infect
sequenc
align
indic
ha
protein
show
homolog
viru
use
herein
challeng
studi
signific
differ
crossprotect
remain
unknown
studi
map
epitop
mab
conduct
understand
antigen
properti
viru
might
contribut
prevent
control
viru
